Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

SMC Update - March 2017

The Scottish Medicines Consortium (SMC) has issued its monthly advice on newly licensed medicines.

Lacosamide (Vimpat®) has been rejected for use as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in adult and adolescent (16-18 years) patients with epilepsy. The manufacturer failed to make a submission.

Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.

Share 'SMC Update - March 2017' on Email Share 'SMC Update - March 2017' on Delicious Share 'SMC Update - March 2017' on Digg Share 'SMC Update - March 2017' on Facebook Share 'SMC Update - March 2017' on Google+ Share 'SMC Update - March 2017' on reddit Share 'SMC Update - March 2017' on StumbleUpon Share 'SMC Update - March 2017' on Twitter

atomic-wealth

No Comments to “SMC Update - March 2017”

Leave a Comment

(required)

(required)


Prescribing Advice for GPs is powered by WordPress.
Subscribe for Free to our RSS or Atom Feeds for New Entries.
Akismet has protected Prescribing Advice for GPs from 788,922 spam comments.

atomic-wealth
fond-illness
summer